Stockbabie NewsFatherMarketNewsMarket Intelligence
MARKETS
Wire · Markets
Markets

Nexentis Technologies' MitoCareX Bio Subsidiary Completes Initial Computational Screening Stage Under Its Drug-Discovery Initiative With Boltz

Oct 26, 2026 · 08:18 AM ET· updated 1h ago

Nexentis Technologies Inc. (NASDAQ: NXTS) ("Nexentis" or the "Company") today announced that its wholly owned subsidiary, MitoCareX Bio Ltd. ("MitoCareX"), has completed an initial computational

Share
Why It Matters

Nexentis finished the first step of searching for new medicines using computer help. When a biotech company moves forward on drug research, it shows progress toward possible future products.

This read is generated by AI from raw market data and is for education only. It is not financial advice, not a signal, and not a recommendation to buy or sell.
Tickers in Play
NXTS0.57
+0.04 (+7.99%)

Last session drawn · prints held ~15 minutes · licensed exchange data

Source: Benzinga · Read the original report at the publisher. Headline and figures shown for context; data may be delayed.

Disclosure: Educational and informational purposes only. Not financial advice. We educate, not advise. Market data may be delayed up to 15 minutes unless marked real-time. Past performance is not indicative of future results.